Literature DB >> 2324685

Infection of monocytes by human immunodeficiency virus type 1 blocked by inhibitors of CD4-gp120 binding, even in the presence of enhancing antibodies.

C F Perno1, M W Baseler, S Broder, R Yarchoan.   

Abstract

Infection of monocyte/macrophages (M/M) by a variety of viruses (including HIV-1) has been shown to be enhanced in the presence of low concentrations of antiviral antibodies. This process has been hypothesized as occurring through binding of the virus-antibody complex to Fc or complement receptors followed by endocytosis. In the current study, we explored whether such a mechanism might provide a CD4-independent route of infection by HIV-1 for any of several populations of M/M. In the absence of anti-HIV antibodies, replication of HIV-1 in M/M was blocked by viral binding inhibitors such as soluble CD4 or OKT4A mAb. Furthermore, while infection of the M/M populations by a low multiplicity of infection of HIV-1 was found to be somewhat enhanced by the presence of very low concentrations of anti-HIV antibodies, this process was also consistently inhibited by recombinant soluble CD4 and by OKT4A antibody. These results suggest that under the variety of conditions studied, CD4 binding was an essential step in the infection of M/M by HIV. Moreover, they are consistent with the notion that "enhancing" antibodies may serve to concentrate HIV onto CD4 receptors or, alternately, may act at other steps in the process of viral entry and replication.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2324685      PMCID: PMC2187849          DOI: 10.1084/jem.171.4.1043

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  33 in total

1.  Infection of monocyte/macrophages by human T lymphotropic virus type III.

Authors:  D D Ho; T R Rota; M S Hirsch
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

2.  Flavivirus infection enhancement in macrophages: radioactive and biological studies on the effect of antibody on viral fate.

Authors:  S W Gollins; J S Porterfield
Journal:  J Gen Virol       Date:  1984-08       Impact factor: 3.891

3.  Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

Authors:  H Mitsuya; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

4.  Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule.

Authors:  J S McDougal; M S Kennedy; J M Sligh; S P Cort; A Mawle; J K Nicholson
Journal:  Science       Date:  1986-01-24       Impact factor: 47.728

5.  In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody.

Authors:  S B Halstead
Journal:  J Infect Dis       Date:  1979-10       Impact factor: 5.226

6.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Authors:  H Mitsuya; K J Weinhold; P A Furman; M H St Clair; S N Lehrman; R C Gallo; D Bolognesi; D W Barry; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

7.  Differential effect of monoclonal anti-DR antibody on monocytes in antigen- and mitogen-stimulated responses: mechanism of inhibition and relationship to interleukin 1 secretion.

Authors:  T L Gerrard; C H Jurgensen; A S Fauci
Journal:  Cell Immunol       Date:  1983-12       Impact factor: 4.868

8.  A new mechanism for the neutralization of enveloped viruses by antiviral antibody.

Authors:  S W Gollins; J S Porterfield
Journal:  Nature       Date:  1986 May 15-21       Impact factor: 49.962

9.  On the entry of Semliki forest virus into BHK-21 cells.

Authors:  A Helenius; J Kartenbeck; K Simons; E Fries
Journal:  J Cell Biol       Date:  1980-02       Impact factor: 10.539

10.  Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody.

Authors:  S B Halstead; E J O'Rourke
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

View more
  20 in total

Review 1.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

2.  Human retinal microglia express candidate receptors for HIV-1 infection.

Authors:  V T Pham; L Wen; P McCluskey; M C Madigan; P L Penfold
Journal:  Br J Ophthalmol       Date:  2005-06       Impact factor: 4.638

3.  HIV-1 infection of in vitro cultured human monocytes: early events and influence of anti HIV-1 antibodies.

Authors:  M Arendrup; S Olofsson; J O Nielsen; J E Hansen
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

4.  Cystamine potently suppresses in vitro HIV replication in acutely and chronically infected human cells.

Authors:  A Bergamini; M Capozzi; L Ghibelli; L Dini; A Salanitro; G Milanese; T Wagner; S Beninati; C D Pesce; C Amici
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

5.  Complex determinants of macrophage tropism in env of simian immunodeficiency virus.

Authors:  K Mori; D J Ringler; T Kodama; R C Desrosiers
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

Review 6.  Anti-AIDS drug development: challenges and strategies.

Authors:  P Mohan
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

Review 7.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

8.  Association of Fcγ receptor IIIa genotype with the rate of HIV infection after gp120 vaccination.

Authors:  Donald N Forthal; Erin E Gabriel; Angela Wang; Gary Landucci; Tran B Phan
Journal:  Blood       Date:  2012-08-22       Impact factor: 22.113

Review 9.  Fc gamma receptors in cancer and infectious disease.

Authors:  M W Fanger; D V Erbe
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

10.  Distinction of human immunodeficiency virus type 1 neutralization and infection enhancement by human monoclonal antibodies to glycoprotein 120.

Authors:  A Takeda; J E Robinson; D D Ho; C Debouck; N L Haigwood; F A Ennis
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.